Skip to main content

Triprolidine (Monograph)

Brand name: Zymine Liquid
Drug class: First Generation Antihistamines

Medically reviewed by Drugs.com on Oct 3, 2023. Written by ASHP.

Introduction

First generation antihistamine; an alkylamine derivative.a

Uses for Triprolidine

Allergic and Nonallergic Rhinitis

Symptomatic relief of seasonal (e.g., hay fever) or perennial (nonseasonal) allergic rhinitis or nonallergic (vasomotor) rhinitis.101 102

Used in fixed combination with other agents (e.g., pseudoephedrine) for symptomatic relief of rhinorrhea, sneezing, oronasopharyngeal itching, lacrimation, itching eyes, and/or other symptoms (e.g., sinus congestion) associated with seasonal or perennial allergic rhinitis or nonallergic rhinitis.102 103 104 105

Allergic Conjunctivitis

Symptomatic relief of allergic conjunctivitis caused by foods or inhaled allergens.101

Allergic Skin Disorders

Symptomatic treatment of mild, uncomplicated allergic skin manifestations of urticaria and angioedema.101

Common Cold

Used in fixed combination with other agents (e.g., pseudoephedrine) for self-medication for symptomatic relief of sinus congestion and other symptoms associated with the common cold.103 104

Triprolidine Dosage and Administration

Administration

Oral Administration

Administer orally as tablets or oral solution.101 102 103 104 a

Dosage

Available as triprolidine hydrochloride; dosage expressed in terms of the salt.101 102 103 104

Individualize dosage according to patient’s response and tolerance.a b

Fixed-combination preparations do not permit individual titration of dosages. When used in fixed combination with other agents (e.g., pseudoephedrine), select a dosage that is within the usual therapeutic range for each ingredient; dosage recommendations of triprolidine hydrochloride for adults and children when administered in fixed combinations are the same as when the drug is used as a single agent.a

Pediatric Patients

Allergic Conditions
Allergic and Nonallergic Rhinitis, Allergic Conjunctivitis, and Allergic Skin Disorders
Oral

Children 4 months to <2 years of age: 0.313 mg every 4–6 hours (as oral solution), not to exceed 1.252 mg in 24 hours.101 m o (See Pediatric Use Under Cautions.)

Children 2 to <4 years of age: 0.625 mg every 4–6 hours (as oral solution), not to exceed 2.5 mg in 24 hours.101 m o

Children 4 to <6 years of age: 0.938 mg every 4–6 hours (as oral solution), not to exceed 3.75 mg in 24 hours.101 m o

Allergic Rhinitis and Allergic Conjunctivitis

Self-medication in children 6 to <12 years of age: 1.25 mg every 4–6 hours (as tablets or oral solution), not to exceed 5 mg in 24 hours.103 104 105 m o

Self-medication in children ≥12 years of age: 2.5 mg every 4–6 hours (as tablets or oral solution), not to exceed 10 mg in 24 hours.103 104 105 m o

Common Cold
Oral

Self-medication in children 6 to <12 years of age: 1.25 mg every 4–6 hours (as tablets or oral solution), not to exceed 5 mg in 24 hours.103 104

Self-medication in children ≥12 years of age: 2.5 mg every 4–6 hours (as tablets or oral solution), not to exceed 10 mg in 24 hours.103 104

Adults

Allergic Conditions
Allergic Rhinitis and Allergic Conjunctivitis
Oral

Self-medication: 2.5 mg every 4–6 hours (as tablets or oral solution), not to exceed 10 mg in 24 hours.103 104 105 m o

Common Cold
Oral

Self-medication: 2.5 mg every 4–6 hours (as tablets or oral solution), not to exceed 10 mg in 24 hours.103 104

Prescribing Limits

Pediatric Patients

Allergic Conditions
Allergic and Nonallergic Rhinitis, Allergic Conjunctivitis, and Allergic Skin Disorders
Oral

Children 4 months to <2 years of age: Maximum 1.252 mg in 24 hours.101 m o

Children 2 to <4 years of age: Maximum 2.5 mg in 24 hours.101 m o

Children 4 to <6 years of age: Maximum 3.75 mg in 24 hours.101 m o

Allergic Rhinitis and Allergic Conjunctivitis

Self-medication in children 6 to <12 years of age: Maximum 5 mg in 24 hours.103 104 105 m o

Self-medication in children ≥12 years of age: Maximum 10 mg in 24 hours.103 104 105 m o

Common Cold
Oral

Self-medication in children 6 to <12 years of age: Maximum 5 mg in 24 hours.103 104

Self-medication in children ≥12 years of age: Maximum 10 mg in 24 hours.103 104

Adults

Allergic Conditions
Allergic Rhinitis and Allergic Conjunctivitis
Oral

Self-medication: Maximum 10 mg in 24 hours.105 m o

Common Cold
Oral

Self-medication: Maximum 10 mg in 24 hours.103 104

Cautions for Triprolidine

Contraindications

Warnings/Precautions

Warnings

Concomitant Diseases

Because of anticholinergic effects, use with extreme caution in patients with angle-closure glaucoma, pyloroduodenal obstruction, bladder-neck obstruction, and symptomatic prostatic hypertrophy.101 102 b

Use with extreme caution in patients with a history of bronchial asthma, increased IOP, hyperthyroidism, or cardiovascular disease (e.g., hypertension).101 102 b

CNS Effects

Risk of drowsiness.102 105 (See CNS Depressants under Interactions and also see Advice to Patients.)

Possible excitability (especially in children).105 (See Pediatric Use under Cautions.)

General Precautions

Use of Fixed Combinations

When used in fixed combination with other agents (e.g., pseudoephedrine), consider the cautions, precautions, and contraindications associated with all ingredients in the formulation.103 104 105 a

Duration of Therapy

When used for self-medication, discontinue therapy and consult a clinician if symptoms persist for >7 days or are accompanied by fever.105

Specific Populations

Pregnancy

Category C.101 102 106

Lactation

Distributed into milk.106 Some manufacturers suggest discontinuing nursing or the drug because of potential risk to nursing infants.101 102 a However, AAP considers triprolidine compatible with breast-feeding.106

Pediatric Use

Use not recommended in premature or full-term neonates.a b (See Contraindications.)

Possible paradoxical excitement (e.g., restlessness, insomnia, tremors, euphoria, nervousness, delirium, palpitation, seizures), especially in children.b

Use in children <4 months of age not recommended.c Children <6 years of age should receive triprolidine only under the direction of a clinician.103 104 c

Risk of overdosage and toxicity (including death) in children <2 years of age receiving OTC preparations containing antihistamines, cough suppressants, expectorants, and nasal decongestants alone or in combination for relief of symptoms of upper respiratory tract infection.r s Limited evidence of efficacy for these preparations in this age group; appropriate dosages not established.r Therefore, FDA recommended not to use such preparations in children <2 years of age;t safety and efficacy in older children under evaluation.v x Because children 2–3 years of age also are at increased risk of overdosage and toxicity, some manufacturers of oral nonprescription cough and cold preparations agreed to voluntarily revise the product labeling to state that such preparations should not be used in children <4 years of age.u v w x FDA recommends that parents and caregivers adhere to dosage instructions and warnings on the product labeling that accompanies the preparation and consult a clinician about any concerns.u v w Clinicians should ask caregivers about use of OTC cough/cold preparations to avoid overdosage.r

Geriatric Use

Possible increased risk of dizziness, sedation, and hypotension in geriatric patients ≥60 years of age.102 b

Common Adverse Effects

Drowsiness,101 dry mouth,101 anorexia,101 nausea,101 vomiting,101 headache,101 dizziness,101 102 nervousness,101 blurred vision,101 polyuria,101 heartburn,101 dysuria,101 urinary retention.101

Drug Interactions

Specific Drugs and Laboratory Tests

Drug or Laboratory Test

Interaction

Comments

CNS depressants (e.g., alcohol, hypnotics, sedatives, tranquilizers, tricyclic antidepressants)

Possible additive CNS depression101 102 105 b

Tricyclic antidepressants prolong and intensify anticholinergic effects of antihistamines101

Avoid concomitant use102 105

MAO inhibitors

MAO inhibitors prolong and intensify anticholinergic effects of antihistamines101 102 b

Avoid use with or for 2 weeks after discontinuance of MAO inhibitors105

Test, antigen or histamine

Inhalation-challenge testing with histamine or antigen: Possible suppression of test responsed e f g h i j k l

Antigen skin testing: Possible suppression of wheal and flare reactionsd e f g h i j k l

Triprolidine Pharmacokinetics

Absorption

Bioavailability

Rapidly absorbed.102

Therapeutic concentration achieved rapidly and usually maintained for 4–8 hours.102

Distribution

Extent

Distributed into milk.106 (See Lactation under Cautions.)

Elimination

Half-life

3–3.3 hours.101 102

Stability

Storage

Oral

Tablets

Tight, light-resistant containers at 15–30°C in a dry place.a

Solution

Tight, light-resistant containers at 15–30°C in a dry place;101 102 105 a do not freeze.a

Actions

Advice to Patients

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Triprolidine Hydrochloride

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Solution

1.25 mg/5 mL*

Triprolidine Hydrochloride Solution

Zymine Liquid

Vindex

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Triprolidine and Pseudoephedrine Hydrochlorides

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Solution

1.25 mg/5 mL Triprolidine Hydrochloride and Pseudoephedrine Hydrochloride 30 mg/5 mL*

Allerfrim Syrup

Rugby

Triprolidine and Pseudoephedrine Hydrochlorides Solution

1.25 mg/5 mL Triprolidine Hydrochloride and Pseudoephedrine Hydrochloride 45 mg/5 mL*

Triprolidine and Pseudoephedrine Hydrochlorides Solution

Zymine-D Liquid

Vindex

Tablets

2.5 mg Triprolidine Hydrochloride and Pseudoephedrine Hydrochloride 60 mg*

Allerfrim

Rugby

Aprodine

Major

Triprolidine and Pseudoephedrine Hydrochlorides Tablets

AHFS DI Essentials™. © Copyright 2024, Selected Revisions October 13, 2015. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

References

101. Vindex Pharmaceuticals, Inc. Zymine (triprolidine hydrochloride) liquid prescribing information. Memphis, TN; 2005 Jul.

102. Vindex Pharmaceuticals, Inc. Zymine-D (triprolidine hydrochloride and pseudoephedrine hydrochloride) liquid prescribing information. Memphis, TN; 2005 Jul.

103. Major Pharmaceuticals. Aprodine (triprolidine hydrochloride and pseudoephedrine hydrochloride ) syrup product information. Livonia, MI. From Major Pharmaceutical website. Accessed 2008 Jan 31. http://major-pharm.com/index.php?NR=consumer

104. Major Pharmaceuticals. Aprodine (triprolidine hydrochloride and pseudoephedrine hydrochloride ) tablets product information. Livonia, MI. From Major Pharmaceutical website. Accessed 2008 Jan 31. http://major-pharm.com/index.php?NR=consumer

105. Rugby. Allerfrim (triprolidine hydrochloride and pseudoephedrine hydrochloride) syrup product information. Duluth, GA; 2004 Jul.

106. Triprolidine. In: Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:1639-40.

500. Food and Drug Administration. Drugs for human use; unapproved and misbranded oral drugs labeled for prescription use and offered for relief of symptoms of cold, cough, or allergy, enforcement action dates. Notice. [Docket No. FDA-2011-N-0100] Fed Regist. 2011; 76:11794-8.

a. AHFS Drug Information 2008. McEvoy GK, ed. Triprolidine Hydrochloride. Bethesda, MD: American Society of Health-System Pharmacists; 2008:24.

b. AHFS Drug Information 2008. McEvoy GK, ed. Antihistamines General Statement. Bethesda, MD: American Society of Health-System Pharmacists; 2008:1-8.

c. Food and Drug Administration. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; tentative final monograph for OTC antihistamine drug products. [21 CFR Part 341] Fed Regist. 1985; 50:2200-18. (IDIS 195256)

d. Cook TJ, MacQueen DM, Wittig HJ et al. Degree and duration of skin test suppression and side effects with antihistamines: a double blind controlled study with five antihistamines. J Allergy Clin Immunol. 1973; 51:71-7. http://www.ncbi.nlm.nih.gov/pubmed/4405284?dopt=AbstractPlus

e. Galant SP, Bullock J, Wong D et al. The inhibitory effect of antiallergy drugs on allergen and histamine induced wheal and flare response. J Allergy Clin Immunol. 1973; 51:11-21. http://www.ncbi.nlm.nih.gov/pubmed/4118408?dopt=AbstractPlus

f. Chipps BE, Talamo RC, Mellits ED et al. Immediate (IgE-mediated) skin testing in the diagnosis of allergic disease. Ann Allergy. 1978; 41:211-5. http://www.ncbi.nlm.nih.gov/pubmed/81630?dopt=AbstractPlus

g. Galant SP, Zippin C, Bullock J et al. Allergy skin test: I. Antihistamine inhibition. Ann Allergy. 1972; 30:53-63. http://www.ncbi.nlm.nih.gov/pubmed/4400814?dopt=AbstractPlus

h. Diamond GA, Dilibero RJ. Pharmacologic modification of the immediate intradermal skin reaction. Ann Allergy. 1966; 24:288-90. http://www.ncbi.nlm.nih.gov/pubmed/5328526?dopt=AbstractPlus

i. Kern GW IV. Letter to the editors. Clin Allergy. 1982; 12:321. http://www.ncbi.nlm.nih.gov/pubmed/6125277?dopt=AbstractPlus

j. Arnaud A, Vervloet D, Ostorero M et al. Effets des anti-histaminiques (H1 et H2) sur différents types de tests cutanés explorant l’allergie a médiation humorale ou cellulaire. (French; with English abstract.) Nouv Presse Med. 1980; 9:2849. Letter.

k. Johnson CE, Weiner JS, Wagner DS et al. Effect of H1- and H2-receptor blockade on the inhibition of immediate cutaneous reactions. Clin Pharm. 1984; 3:60-4. http://www.ncbi.nlm.nih.gov/pubmed/6141860?dopt=AbstractPlus

l. Smith JA, Mansfield LE, de Shazo RD. An evaluation of the pharmacologic inhibition of the immediate and late cutaneous reaction to allergen. J Allergy Clin Immunol. 1980; 65:118-21.

m. Food and Drug Administration. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; tentative final monograph for OTC antihistamine drug products. [21 CFR Parts 201, 310, 341, 369] Fed Regist. 1987; 52:31892-914.

n. Food and Drug Administration. Nighttime sleep-aid products for over-the-counter human use; final monograph. [21 CFR Part 338] Fed Regist. 1989; 54:6814-27. (IDIS 250549)

o. Food and Drug Administration. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; final monograph for OTC antihistamine drug products. 21 CFR Parts 201, 310, 341, and 369. Final rule. [Docket No. 76N-052H] Fed Regist. 1992; 57:58356-76.

p. Novartis. Tavist (clemastine fumarate) tablets prescribing information. In: Physicians’ desk reference for nonprescription drugs. 52nd edition. Montvale NJ: Medical Economics Company Inc; 1998:708-9.

q. Warner-Lambert. Actifed cold and allergy tablets prescribing information. In: Physicians’ desk reference for nonprescription drugs. 52nd edition. Montvale NJ: Medical Economics Company Inc; 1998:798.

r. Srinivasan A, Budnitz D, Shehab N et al. Infant deaths associated with cough and cold medications—two states, 2005. MMWR Morb Mortal Wkly Rep. 2007; 56:1-4. http://www.ncbi.nlm.nih.gov/pubmed/17218934?dopt=AbstractPlus

s. Food and Drug Administration. Cough and cold medications in children less than two years of age. Rockville, MD; 2007 Jan 12. From FDA website. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150441.htm

t. Food and Drug Administration. FDA news: FDA releases recommendations regarding use of over-the-counter cough and cold products. Rockville, MD; 2008 Jan 17. From the FDA web site. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008

u. Food and Drug Administration. Over the counter cough and cold medications. Rockville, MD; October 2008. From FDA website. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm094913.htm

v. Food and Drug Administration. FDA statement: FDA statement following CHPA’s announcement on nonprescription over-the-counter cough and cold medicines in children. 2008 Oct 8. From the FDA website. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116964.htm

w. Consumer Healthcare Products Association. Statement from CHPA on the voluntary label updates to oral OTC children’s cough and cold medicines. 2008 Oct 7. http://www.chpa-info.org/10_07_08_pedcc.aspx

x. Heavey S. Don’t use cold drugs in kids under 4: manufacturers. Reuters, 2008 Oct 8. From Reuters website. http://uk.reuters.com/articlePrint?articleId=UKTRE4965S520081008

Frequently asked questions